Bempegaldesleukin
As of the edition of 20 October 2026, Bempegaldesleukin is a protein: stopped in 2022; acts on IL2RB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Protein
- Registered trials
- 21, 10 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 companies on route A because of this drug.
Companies on route A for this drug
In the product4 companies are on route A because of Bempegaldesleukin.
See the 4 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL2RB | Interleukin-2 receptor subunit beta | P14784 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 3 | 0 | 2 |
| Phase 2 | 11 | 4 | 2 | 5 |
| Phase 3 | 5 | 2 | 0 | 3 |
| All trials | 21 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Nektar Therapeutics | Lead sponsor of trials | 2015 to now |
| Nykode Therapeutics ASA | Lead sponsor of trials | 2018 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2018 to now |
| Calithera Biosciences | Lead sponsor of trials | 2019 to now |
| Pfizer | Lead sponsor of trials | 2019 to now |